title: High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.
abstract: OBJECTIVE
  To report our experience of high-dose chemotherapy (HDC) with haematopoietic stem-cell support (HSC) in patients with poor risk, relapsed or refractory germ cell tumours (GCTs), as this treatment might offer effective salvage for patients with disseminated GCTs.
  
  
  METHODS
  We retrospectively reviewed the medical records and database for 33 patients with GCT who were treated with HDC with HSC in our centres.
  
  
  RESULTS
  Thirty-three patients were treated with either one or two cycles of carboplatin and etoposide-based HDC with HSC support, between March 1990 and October 2003. Twenty-six patients (79%) had nonseminomatous GCT, six seminoma (18%), and one (3%) a combined seminoma and teratoma. Twenty patients (60%) had previously had a clinical complete response after previous chemotherapy +/- surgery for residual disease. Most patients were treated with HDC for relapsing (49%) or relative refractory disease (30%), but seven (21%) had HDC in the first partial remission. The complete response rate to HDC was 58%. There were two treatment-related deaths (6%). As of April 2005, 18 patients were alive and disease-free with a median (range) follow-up of 72 (0.5-174) months. The 5-year overall and progression-free survival probabilities were 57% and 56%, respectively. The median (range) times to absolute neutrophil count recovery (> or = 500/microL) were 13 (9-24) and 12 (10-15) days, and for platelet count recovery ( > or = 20,000/microL) were 16 (7-50) and 13 (11-17) days, in the first and second cycles, respectively.
  
  
  CONCLUSIONS
  The role of HDC with HSC support in metastatic GCTs remains controversial, and data from randomized controlled trials are needed. Our experience suggests that, in selected patients, this approach might be a useful form of salvage therapy.
authors.affiliation: Cancer Research Centre, Weston Park Hospital, Sheffield, UK.
authors.forename: Loaie M
authors.initials: LM
authors.lastname: El-Helw
authors.forename: Jay D
authors.initials: JD
authors.lastname: Naik
authors.forename: John D
authors.initials: JD
authors.lastname: Chester
authors.forename: Johnathan K
authors.initials: JK
authors.lastname: Joffe
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Selby
authors.forename: Robert E
authors.initials: RE
authors.lastname: Coleman
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy*; D012186:Retroperitoneal Neoplasms / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014565:Urogenital Neoplasms / Q000628:therapy*